Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal
Author:
Publisher
Informa UK Limited
Subject
Pharmacology (medical),Neurology (clinical),General Neuroscience
Link
http://www.tandfonline.com/doi/pdf/10.1586/14737175.2015.1058162
Reference153 articles.
1. Is it time for a new global classification of multiple sclerosis?
2. Defining the clinical course of multiple sclerosis: The 2013 revisions
3. Update on Disease-Modifying Treatments for Multiple Sclerosis
4. Fingolimod
5. Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis
Cited by 29 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Safety and Discontinuation Rate of Dimethyl Fumarate (Zadiva®) in Patients with Multiple Sclerosis: An Observational Retrospective Study;Journal of Clinical Medicine;2023-07-27
2. Favorable benefit–risk ratio with teriflunomide treatment in relapsing-remitting multiple sclerosis: Results of the 2-year, multicenter, prospective, noninterventional TAURUS MS study in Austria;eNeurologicalSci;2022-06
3. Injectable versus oral first-line multiple sclerosis therapies: knows and unknowns from observational studies;Neural Regeneration Research;2022
4. First‐line therapies in late‐onset multiple sclerosis: An Italian registry study;European Journal of Neurology;2021-07-30
5. Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study;Neurotherapeutics;2021-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3